Molecular alterations in cancer genes and associated signaling pathways are used to inform
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …

Cancer therapies that target key molecules have not fulfilled expected promises for most
common malignancies. Major challenges include the incomplete understanding and …

Building on years of basic scientific discovery, recent advances in the fields of cancer
genetics and medicinal chemistry are now converging to revolutionize the treatment of …

Signal transduction therapy for cancer targets signaling elements with key roles in cancer
cell survival and proliferation, but with more minor roles in the survival of healthy cells …

Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and
produce aggressive malignancies that causes millions of deaths every year. With the new …

Most experimental cancer drugs ultimately fail during the course of clinical development,
contributing to the high cost of the few that are granted regulatory approval. Moreover …

Drugs that target intracellular signalling pathways have markedly improved progression-free
survival of patients with cancers who were previously regarded as untreatable. However, the …

New molecular insight reveals novel points of attack for targeted cancer therapy. The recent
advances in cancer genomics and novel insight into the complex biology of cancer make the …

Mutated or dysregulated transcription factors represent a unique class of drug targets that
mediate aberrant gene expression, including blockade of differentiation and cell death gene …

Targeted therapies can be defined as drugs developed against a specific target based on its
important biological function in cancer. In contrast, nontargeted therapies are drugs …